Immunosuppressive drugs result in global attenuation of the immune response with potential fatal side effects, thus, limiting their utility in treating autoimmune diseases. A more effective approach would involve antigen specific inactivation of autoreactive T cells. The role of the costimulatory molecule CTLA-4 in tolerance induction has been well documented. In spite of the significant tolerogenic response that was observed in our earlier, there are two potential limitations to the targeted delivery of CTLA-4 signaling. The first is a limited accessibility to certain large target tissues second is the need necessary to link anti-CTLA-4 antibody to different tissue specific antibodies for different targets. Further, this strategy may not be effective in treating systemic autoimmune conditions. To overcome these potential limitations, we have recently designed a novel strategy by using matured dendritic cells (DCs) as APCs and manipulating the interaction at the immunological synapse through a DC bound cross-linking anti-CTLA-4 antibody to induce regulatory T cells and tolerance to a specific antigen presented by DCs. The major advantages of this system are 1) one BiAb can be used to induce tolerance to any number of antigens; 2) it can be used to tolerize T cells against autoantigens of systemic as well as organ specific autoimmune diseases and also can induce tolerance to allergens, allo- and xeno-antigens, etc; 3) in vivo injected DCs could migrate into lymphoid structures and target organs throughout the body and inactivate antigen specific T cells; 4) use of the exceptional antigen presenting capability of DCs that could induce a much stronger regulatory T cell expansion and tolerance. ? ? Here, we propose to determine the therapeutic potential of an anti-CTLA-4 antibody coated dendritic cells and in inducing regulatory T cells.
In aim -l, we will test the efficacy of BiAb in inducing regulatory T cells in vivo and in vitro.
In aim -2, we will test the ability of these regulatory T cells in down modulating EAT and CIA. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI059745-02
Application #
6870226
Study Section
Immunological Sciences Study Section (IMS)
Program Officer
Esch, Thomas R
Project Start
2004-04-01
Project End
2006-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$193,750
Indirect Cost
Name
University of Illinois at Chicago
Department
Surgery
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Tsuboi, Naotake; Ernandez, Thomas; Li, Xun et al. (2011) Regulation of human neutrophil Fc? receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum 63:467-78
Nigrovic, Peter A; Malbec, Odile; Lu, Bao et al. (2010) C5a receptor enables participation of mast cells in immune complex arthritis independently of Fc? receptor modulation. Arthritis Rheum 62:3322-33
Karumuthil-Melethil, Subha; Perez, Nicolas; Li, Ruobing et al. (2008) Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J Immunol 181:8323-34
Li, Ruobing; Perez, Nicolas; Karumuthil-Melethil, Subha et al. (2007) Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol 179:5191-203